Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients

doi:10.21203/rs.3.rs-3894346/v1

Download PDF

Research Article

Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients

https://doi.org/10.21203/rs.3.rs-3894346/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 29 May, 2024

Read the published version in Annals of Hematology →

You are reading this latest preprint version

Reduced-toxicity conditioning (RIC) regimens are used for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older patients. However, successful outcomes are still hindered by graft-versus-host disease (GVHD), treatment-related mortality (TRM) and relapse, especially in the setting of haploidentical donor (HID) hematopoietic cell transplantation (HCT). The aim of this study was to evaluate the effectiveness of a RIC conditioning regimen that included a combination of lower doses of post-transplantation cyclophosphamide (PTCy) (40 mg/kg on day +3) and anti-thymocyte globulin (ATG) (7.5 mg/kg) as GVHD prophylaxis, followed by haplo stem cell transplantation (SCT) in older patients.

Method: We retrospectively analyzed 55 patients ≥ 55 years of age with hematologic malignancies treated with fludarabine, Cytarabine, busulfan, and low dose cyclophosphamide as the conditioning regimen between January 1, 2019 and

November 30, 2023.

Results: Neutrophil engraftment was successful in all the patients within 28 days, with 54 (98.2%) patients achieving complete donor chimerism. The cumulative incidence of non-relapse mortality was 0 at 30 days, 7.5% at 100 days and 19% at 1-year. The cumulative incidence of grade II-IV aGVHD was 25% (95%CI,15%−38%), while grade III-IV aGVHD was 9.1% (95%CI,3.3%−19%). The cumulative incidence of extensive cGVHD at 1 year was 3.6% (95%CI,0.66%-11%). The cumulative incidence of relapse (CIR), overall survival (OS) and GVHD-free/relapse-free survival (GRFS) at 1-year were 9.0%, 71.6%, and 67.1%, respectively.

Conclusions: These results suggested that a RIC conditioning regimen including a combination of lower PTCy/ATG as GVHD prophylaxis, followed by haplo-SCTmight be a promising option for appropriately selected older patients.

Haploidentical stem cell transplantation

Reduced-toxicity conditioning regimen

Post-transplantation cyclophosphamide

Anti-thymocyte globulin

Older patients

The incidence of hematologic malignancies is expected to rise in elderly people due to aging of the world population [1, 2]. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has the potential to cure or improve outcomes of many of these diseases [1, 3]. However, historically the use of allo-HSCT has been hampered in older adults due to the lack of an HLA-matched donor, age-associated comorbidities, and lower performance status in this age group of patients, in addition to a more aggressive nature of the disease [3]. An increasing number of studies have demonstrated that a reduced intensity conditioning (RIC) regimen combined with a haploidentical donor (HID) is a feasible option when a matched sibling donor or unrelated donor is unavailable for older adults [4–6].

It is well established that the risk of graft-versus-host disease (GVHD) increases with age and the use of a peripheral blood stem cell (PBSC) graft [7–11]. In the last decade, several reports have described that the outcome of older patients undergoing haplo-SCT has improved due to effective prophylaxis strategies for acute or chronic GVHD. A regimen of post-transplantation cyclophosphamide (PTCy) for GVHD prophylaxis has recently become a feasible option in patients older than 55 years or even 76 years receiving a haplo-SCT [12–15]. Nevertheless, the cumulative incidence (CI) of II-IV acute GVHD (aGVHD) has remained at the high levels of 37–40% [16–18], while chronic GVHD (cGVHD) has a CI of 26–42% [15, 18]. It is worth noting that a high risks of aGVHD and cGVHD are associated with the source of PBSC graft rather than bone marrow (BM) graft in haplo-SCT with PTCy used for GVHD prophylaxis [19]. Compared with anti-thymocyte globulin (ATG)-based regimens for GVHD prophylaxis, PTCy has been shown to be associated with lower incidences of viral and fungal infections [20]. Luznik et al. [21] retrospectively analyzed the effects of different doses of PTCy (two doses of PTCy on day + 3, +4 vs. one dose of PTCy on day + 3) on the results of transplantation in haplo-SCT with PTCy. The data indicated that one dose of PTCy had the same effect on GVHD prophylaxis as two doses of PTCy, although there was a trend towards a higher risk of cGVHD, especially serious cGVHD.

In recent years, a total ATG dose of 10 mg/kg has been used for prevention of GVHD, followed by haplo-SCT and has been shown to be beneficial for reducing acute and chronic GVHD in older patients. However, the use of ATG increases the chances of cytomegalovirus (CMV) infections due to a delay in immune reconstitution, with the 100-day CIs of CMV and EBV viremia being 68% and 50%, respectively [5]. Over the last decade, the efficacy and safety of modified combinations of PTCy and ATG have reduced the risk of GVHD in haplo-SCT without influencing other outcomes [20, 22–25]. Our previous study reported that the use of a combination of PTCy (50 mg/kg on day + 3) with ATG (7.5 mg/kg) as GVHD prophylaxis for HID in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) had a better 2-year GRFS rate, lower 180-day incidence of II-IV acute GVHD (aGVHD), lower 1-year incidence of moderate to severe cGVHD and comparable CIR rates than that observed in the standard prophylaxis regimen group [26]. Although the combination of PTCy and ATG has dramatically improved the outcomes of HID in younger patients [27, 28], evidence regarding its efficacy with HID is scarce in older patients. To decrease the risk of aGVHD or cGVHD and lower CMV or EBV reactivation, the current study retrospectively investigated the effect of a novel RIC regimen that included a combination of lower doses of PTCy and ATG on transplant outcomes in patients aged > 55 years who underwent a haplo-HCT. The study showed encouraging results for this novel regimen in older patients undergoing haplo-SCT.

Study design and data collection

The study was a retrospective design based on the transplantation database of the Affiliated People's Hospital of Ningbo University. The inclusion criteria were patients aged ≥ 55 years diagnosed with hematologic malignancies who underwent a haplo-SCT and received an RIC regimen for GVHD prophylaxis of low dose PTCy and low-dose ATG. The study was approved by the institutional review board and was carried out in accordance with the principles of the Declaration of Helsinki. The variables collected from the medical records of the patients included clinical features, pre-transplant-related parameters, transplant-related parameters, post-transplant outcomes, and adverse events. Written informed consent for all aspects of the study was obtained when a patient was admitted to our center.

Conditioning and other transplant procedures

All patients received RIC regimens that consisted of the following agents: fludarabine (30 mg/m²/day) from days − 9 to − 7; Cytarabine (2 g/m²/day) on days − 9 and − 7; busulfan (7.2 mg/kg, in 12 doses) on days − 6, −5, and − 4; cyclophosphamide (1.2 g/m²/day) on day − 3; semustine (250 mg/m², orally) on day − 2, and ATG (7.5 mg/kg, rabbit, [SangStat, Lyon, France]) on days − 5, −4, − 3, and − 2. Ten (18.2%) patients were transplanted with a combination of bone marrow (BM) and PBSC grafts, while 45 (81.80%) patients received only PBSC grafts. Cyclosporin A (CsA), methotrexate (MTX) (on day + 1), mycophenolate (MMF) and PTCy 40 mg/kg on day + 3 were administered to patients for GVHD prophylaxis. MMF was stopped at day + 30, while CsA was tapered from day + 90 if there was no evidence of GVHD, and then stopped on day + 180.

Evaluation points

The study focused mainly on transplant-related mortality (TRM), engraftment, GVHD, infection, relapse, overall survival (OS), and GVHD-free/relapse-free survival (GRFS). TRM was defined as any cause of death other than relapse. Time to neutrophil engraftment and platelet engraftment were defined as the first three consecutive days when the absolute neutrophil count was ≥ 0.5 × 10⁹/L or the platelet count was ≥ 20 ×10⁹/L without transfusion requirements, respectively. Hematopoietic chimerism was defined as the presence of 95% donor hematopoietic cells evaluated by Short Tandem Repeat analysis. AGVHD and cGVHD were graded based on previously described criteria [29]. Disease relapse (if complete remission had been achieved before allo-HSCT) was defined by reappearance of signs of disease, confirmed by either cytology or histology. GRFS was calculated from the allograft date to the last date of follow-up or development of either III-IV acute GVHD, extensive chronic GVHD, relapse, or death [30].

Statistical analysis

Continuous variables were expressed as the median and categorical variables as percentages. The chi-square test was used to analyze categorical variables, while the quantitative data were analyzed using the rank sum test. Transplant outcomes were measured in terms of TRM, engraftment, GVHD, CIR, OS and GRFS. The curves for TRM, GVHD, and CIR were plotted using estimates of CI by the competing risk model. We considered death without engraftment as the competing event for engraftment, death without GVHD as the competing event for GVHD, relapse without TRM as the competing event for TRM, and TRM without relapse as the competing event for CIR. The survival curves for OS and GRFS were plotted using the Kaplan–Meier method.

As this retrospective analysis was designed as an exploratory investigation, no statistical sample size (i.e., power) calculation was conducted. The endpoint of the last follow-up for all the surviving patients was November 30, 2023. SPSS25.0 (IBM, Chicago, IL, USA) was used for the statistical analyses and R version 4.3.0 (http://www.r-project.org) software was used for the competing risks analysis. A P value < 0.05 was considered statistically significant.

Patient and donor characteristics

From January 1, 2019 to November 30, 2023, a total of 55 consecutive patients 55 years or older were included in the study, with a median follow-up period of 11.7 (1.0−57.2) months. The median age of the 55 patients was 59 (55−71) years old, with 8 (14.5%) having an HCT−CI ≥3. The most common diagnoses were AML and MDS. The details of the pre-transplant patients, disease, transplant characteristics, and donor characteristics are shown in Table 1.

Transplant outcomes

The CI of TRM in the patients at days 30 and 100 and 1-year were 0%, 7.5% (95% CI, 2.4–17%), and 19% (95% CI, 9.1–31%), respectively. Sixteen (29.1%) of the patients died during the study period, 4 (25%) due primarily to a relapse, 1 (6.3%) due to GVHD, 2 (12.5%) developed thrombotic microangiopathy, 1(6.3%) due to demyelinating disease, 1 (6.3%) due to an EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement, and 7 (43.8%) due to infection. The causes of death in the 7 infected patients were COVID-19 pneumonia early post-transplant (n=3), CMV pneumonia (n=2), Pneumocystis carinii pneumonia (n=1) and an abdominal infection (n=1).

Engraftment and chimerism

All 55 patients achieved hematopoietic reconstitution within 28 days. Neutrophil reconstruction occurred at a median of 12 (9−23) days. One patient did not achieve full donor chimerism and was rescued with a donor lymphocyte infusion on day 46 and thereafter achieved complete donor chimerism. Fifty-three patients (96.4%) achieved platelet engraftment with a median time of 12 (8−106) days after HSCT. The CI of platelet reconstruction at 100 days was 94.5%. Two patients did not achieve platelet engraftment due to a TRM. A secondary graft failure (SGF) without evidence of relapse was observed in one case on day 31.

Graft versus host disease

Thirty (54.5%) patients developed aGVHD within 100 days. The median onset time of grade II–IV aGVHD was 21.5 (9–71) days after transplantation. The CI of grade II–IV aGVHD and grade III–IV aGVHD at 100 days was 25.0% (95%CI, 15%−38%) and 9.1% (95%CI, 3.3%−19%), respectively (Figs. 1A, 1B). cGVHD was evaluated in those patients who survived more than 100 days after transplantation, with 26 developing cGVHD and two developing extensive cGVHD. The CI of cGVHD at 1 year was 45% (95%CI,32%−58%), while cGVHD requiring systemic therapy was 3.6% (95%CI, 0.66%−11%) (Figs. 1C, 1D). One patient died of IV gut aGVHD.

Infections

Thirty-four (61.8%) patients experienced CMV reactivation post HSCT, while three patients developed CMV disease (pneumonia) on days 40, 283, and 401. The median time to document CMV viremia was 40 (18–283) days post-HSCT, with a median CMV level of 3.11 (0.531∼10000) ×10³ copies/ml. Twenty-three (41.8%) patients developed EBV reactivation, with a median time of 67 (21–479) days post-HSCT and a median EBV level of 4.73 (0.51∼10000) ×10³ copies/ml. The incidence of other major infectious complications, including sepsis, invasive fungal infection, and COVID-19 infection are shown in Table 2.

Survival outcomes

Thirty-nine patients were still alive at the last follow-up. The 1-year CIR after transplantation was 9.0% (95%CI, 2.8%−20%), while the 1-year cumulative incidence of OS and GRFS was 71.6% (95% CI, 64.8%–78.4%) and 67.1% (95% CI, 60.2%–74.0%), respectively (Fig 2).

This study, for the first time, evaluated the feasibility and effectiveness of haplo-SCT with PTCy/ATG retrospectively in the 55 older patients with hematological malignancies (AL 72.7%). The patients received a novel RIC regimen of fludarabine, Cytarabine, busulfan, and low dose of cyclophosphamide. We showed that patients up to the age of 71 years can achieve an acceptable TRM, GVHD, relapse rate, GRFS, and survival using this novel approach.

GVHD historically has been considered the most common and potentially life-threatening transplant-related complication. Several studies have confirmed that the risk of developing GVHD is higher in older patients [7, 8, 31, 32] and to address this problem, various strategies for GVHD prophylaxis have been developed. ATG has been used widely to reduce GVHD in an HLA-mismatched allo-HSCT in elderly patients [5, 33–35]. Sun et al. [5] reported the results for ATG (10 mg/kg) combined with CsA as GVHD prophylaxis in 50 older patients with hematological diseases, with 80% receiving a combination of bone marrow and peripheral blood as grafts. The results showed a lower CI for grades II − IV aGVHD and cGVHD. However, there are reports that using PBSC might lead to higher rates of GVHD compared to the use of bone marrow stem cells [23, 36, 37]. This led us to speculate that the use of bone marrow in 80% of patients in Sun et al.’s study may have contributed to the low incidence of GVHD. Most studies have reported that ATG-based regimens for preventing GVHD in HID transplantation in older patients were associated with relatively high risks of aGVHD, with the incidence of grades II–IV ranging between 29.5–45.6% [33–35], Taken together, these results highlight the importance of optimizing ATG-based regimens in elderly patients receiving GVHD prophylaxis using haplo-SCT, especially in HID-PBSCT. Many studies have investigated the use of PTCy-based regimens including HID for allo-HSCT to decrease the risk of GVHD in older patients. However, the results of these studies are unsatisfactory with an incidence of II − IV aGVHD and cGVHD of 29 − 35% and 11 − 33%, respectively [38–40]. Another retrospective report of a variety of donors who underwent an allo-HSCT using ATG (4.5mg/kg) combined with PTCy (50mg/kg, on days + 3, +4 ) for GVHD prophylaxis, showed that the CIs for grade II − IV aGVHD at day 100 was 11 (5 − 21)%, and for 2 − year cGVHD was 26 (16 − 38)% [41]. While this encouraging result appears to offer a promising method for GVHD prophylaxis only 12 (19%) cases of haplo-SCT were included in the report. To date, no studies have investigated older patients who underwent a haplo-SCT and received lower doses of PTCy combined with ATG for GVHD prophylaxis. Despite the fact that up to 81.8% of the patients in our study received PBSC as a graft, we showed that the CIs for grades II − IV aGVHD and grades III − IV aGVHD at 100 days post-transplantation were 25.0% (95%CI,15%−38%) and 9.1% (95%CI,3.3%−19%), respectively using haplo-SCT and low-dose PTCy and ATG regimen for GVHD prophylaxis. We also showed a lower incidence of moderate-severe cGVHD at 1 year in older individuals who received the PTCy-ATG combination. Moreover, the incidence of CMV reactivation and EBV reactivation was acceptable. These results suggested that low-dose PTCy-ATG effectively and safely prevents aGVHD and cGVHD in elderly patients undergoing a haplo-SCT.

Traditionally, haplo-SCT in older individuals has a higher TRM because of the patient's accumulation of co-morbidities, poor performance status, and acute or chronic GVHD. In a previous study Raiola et al. [39] investigated 634 patients who underwent unmanipulated haploidentical bone marrow transplantation and showed a correlation between age and TRM, with those older than 60 years having a 4.5-fold increased risk of TRM compared to that of younger patients. Three retrospective studies in older patients who received RIC or nonmyeloablative HLA-haploidentical transplantation also demonstrated that the incidence of non-relapse mortality was 6 − 21% at 100 days and 12 − 30% at 1-year [4, 5, 19, 31, 42]. The results of the current study also showed relatively low CIs for TRM in patients of 7.5% at 100 days, and 19.0% at 1-year. In contrast, a report from the Fred Hutchinson Cancer Research Center [43] showed the rate of TRM appeared to increase with higher HCT-CI scores. The reason our study had relatively lower rates of TRM might be because the patients had relatively lower HCT-CI scores, with only 18.4% of patients having a score ≥ 3. Most reports of allo-HSCT in older patients have considered fludarabine-based conditioning regimens historically have lower transplant-related mortality compared to that of busulfan plus cyclophosphamide [5, 44]. We also used a novel RIC regimen consisting of low doses of Cy (1,200 mg/m²/day, on day − 3) and fludarabine, and this may be another reason for the lower TRM we observed. Furthermore, GVHD represents the main source of NRM in transplant patients. For example, only one patient in our study died from GVHD, whereas seven (43.8%) died from infection. Of note, nearly half of the HSCT recipients in the group died of COVID-19 pneumonia in the early post-transplant phase due to the absence of a pathogen-specific adaptive immune response. These data imply that immune recovery was slower in our study, with the results showing there is room for further improvement in our novel conditioning regimen, such as reducing the total dosage of ATG.

To our knowledge, a relapse of malignancy is the predominant cause of treatment failure and death in patients receiving the RIC regimen. At our center, we used fludarabine -intensified RIC regimens and a combination of ATG and PTCy for GVHD prophylaxis. Interestingly, despite one-third of patients in this series not being in complete remission at the time of transplant, we observed a low and encouraging 1-year CIR after transplantation of only 9.0% that compared favorably with the incidence reported in previous studies [4, 5, 34, 45]. A reasonable interpretation of this relatively lower CIR is that the combination of fludarabine with high dosage Ara-C in the preconditioning regimen for AML and MDS may have enhanced the intensity of the pretreatment regimen and reduced later recurrence. This possibility agrees with the findings of Cao et al[26]. Several studies have also shown that HID with PBSC as the stem cell source rather than bone marrow grafts has stronger graft-versus-leukemia (GVL) and results in lower relapse rates [19, 46–48]. The association between the level of GVHD prevention and the risk of relapse has been debated previously. A report on 133 older patients undergoing allo-HSCT showed that the risk of relapse was like that observed between the combination of PTCy/ATG for GVHD prophylaxis and other regimens[41]. These data suggest that potent suppression of GVHD can be accomplished with dual in vivo TCD without a corresponding increase in the risk of relapse. The patient cohort in our study differed from other studies in that it was limited to patients older than 55 years and included more recently treated patients in whom our novel conditioning regimen became more focused on PBSC as the graft type. However, the heterogeneity and relatively small number of patients, the short follow-up time, and possible selection bias when choosing candidates could not be excluded as potential confounding factors in the study and may have contributed to the low CIR we observed.

The current study had some limitations as it was carried out at a single center on a small number of patients with heterogeneous characteristics, making it difficult to perform a multivariable analysis. In addition, post-transplant immune reconstitution data was not monitored routinely in the 55 patients and therefore we could not assess whether administration of PTCy/ATG as the GVHD prophylaxis regimen affected immune reestablishment.

In conclusion, the findings of this study suggest that a low dose PTCy/ATG regimen following a RIC regimen is an effective therapeutic strategy for appropriately selected patients aged 55 years and older with hematologic malignancies.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the ethics committee of the institution.

Funding

This study was funded by the Zhejiang Provincial Medical and Health Science and Technology Project (2022KY1184, 2024KY1602, 2024KY1601), Ningbo Public Welfare Science and Technology Planning Project (2022S020),and Ningbo Clinical Research Center for Ophthalmology (2022L003), China.

Author Contribution

P.P.Y. and Y.L. were the principal investigator who took primary responsibility for this study. P.P.Y. wrote the manuscript. Y.L.,M.J.W. and R.Z.P. participated in statistical analysis and commented on the manuscript. P.P.Y., Y.F., J.J.Y. and J.J.C. collected data and interpreted results and participated in clinical data management. H.H.Z. helped to revise the manuscript. and both authors gave final approval for the manuscript.

Authors’ contributions

Ustun C, Le-Rademacher J, Wang HL et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia 33:2599–2609. http://dx.doi.org/10.1038/s41375-019-0477-x
Kanapuru B, Singh H, Kwitkowski V, Blumenthal G, Farrell AT, Pazdur R (2020) Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation. Blood Rev 43:100670. http://dx.doi.org/10.1016/j.blre.2020.100670
Ciurea SO, Rodrigues M, Giralt S, de Lima M (2009) Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence? Clin Lymphoma Myeloma 9:289–297. http://dx.doi.org/10.3816/CLM.2009.n.057
Kasamon YL, Bolanos-Meade J, Prince GT et al (2015) Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol 33:3152–3161. http://dx.doi.org/10.1200/JCO.2014.60.4777
Sun YQ, Han TT, Wang Y et al (2021) Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Front Oncol 11:639502. http://dx.doi.org/10.3389/fonc.2021.639502
Huang J, Huang F, Fan Z et al (2020) Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study. Cancer Med 9:6244–6255. http://dx.doi.org/10.1002/cam4.3290
Flowers ME, Inamoto Y, Carpenter PA et al (2011) Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117:3214–3219. http://dx.doi.org/10.1182/blood-2010-08-302109
Jagasia M, Arora M, Flowers ME et al (2012) Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 119:296–307. http://dx.doi.org/10.1182/blood-2011-06-364265
George B, Kulkarni U, Lionel S et al (2022) Haploidentical transplantation is feasible and associated with reasonable outcomes despite major infective complications-A single center experience from India. Transpl Cell Ther 28. http://dx.doi.org/10.1016/j.jtct.2021.09.020. 45 e1- e8
Wang Y, Liu DH, Liu KY et al (2013) Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 119:978–985. http://dx.doi.org/10.1002/cncr.27761
Zhao AT, Sung AD (2022) Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies. Curr Oncol Rep 24:125–133. http://dx.doi.org/10.1007/s11912-022-01194-3
Rimando J, McCurdy SR, Luznik L (2023) How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood 141:49–59. http://dx.doi.org/10.1182/blood.2021015129
McCurdy SR, Zhang MJ, St Martin A et al (2018) Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv 2:299–307. http://dx.doi.org/10.1182/bloodadvances.2017014829
DeZern AE, Franklin C, Tsai HL et al (2021) Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv 5:1360–1368. http://dx.doi.org/10.1182/bloodadvances.2020003922
Robinson TM, Fuchs EJ, Zhang MJ et al (2018) Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv 2:1180–1186. http://dx.doi.org/10.1182/bloodadvances.2018018291
Mehta RS, Saliba RM, Ghanem S et al (2022) Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transpl Cell Ther 28. http://dx.doi.org/10.1016/j.jtct.2022.04.020. 395 e1- e11
Devillier R, Granata A, Furst S et al (2017) Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients. Br J Haematol 176:132–135. http://dx.doi.org/10.1111/bjh.13923
Devillier R, Galimard JE, Labopin M et al (2022) Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone Marrow Transplant 57:1421–1427. http://dx.doi.org/10.1038/s41409-022-01674-x
Bashey A, Zhang MJ, McCurdy SR et al (2017) Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol 35:3002–3009. http://dx.doi.org/10.1200/JCO.2017.72.8428
Yang J, Jiang J, Cai Y et al (2019) Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study. Bone Marrow Transplant 54:1049–1057. http://dx.doi.org/10.1038/s41409-018-0382-3
Luznik L, O'Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650. http://dx.doi.org/10.1016/j.bbmt.2008.03.005
Barkhordar M, Kasaeian A, Janbabai G et al (2022) Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia. Front Immunol 13:921293. http://dx.doi.org/10.3389/fimmu.2022.921293
Salas MQ, Prem S, Atenafu EG et al (2020) Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transplant 55:1773–1783. http://dx.doi.org/10.1038/s41409-020-0813-9
Makanga DR, Guillaume T, Willem C et al (2020) Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. J Immunol 205:1441–1448. http://dx.doi.org/10.4049/jimmunol.2000578
Xu X, Yang J, Cai Y et al (2021) Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood. Bone Marrow Transplant 56:705–708. http://dx.doi.org/10.1038/s41409-020-01047-2
Cao J, Pei R, Lu Y et al (2023) Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome. Curr Res Transl Med 71:103360. http://dx.doi.org/10.1016/j.retram.2022.103360
Law AD, Salas MQ, Lam W et al (2018) Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biol Blood Marrow Transplant 24:2259–2264. http://dx.doi.org/10.1016/j.bbmt.2018.07.008
Wang Y, Wu DP, Liu QF et al (2019) Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol 12:88. http://dx.doi.org/10.1186/s13045-019-0781-y
Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-8
Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A (2016) Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 51:610–611. http://dx.doi.org/10.1038/bmt.2015.305
McClune BL, Weisdorf DJ, Pedersen TL et al (2010) Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878–1887. http://dx.doi.org/10.1200/JCO.2009.25.4821
Koreth J, Aldridge J, Kim HT et al (2010) Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 16:792–800. http://dx.doi.org/10.1016/j.bbmt.2009.12.537
van der Velden W, Choi G, de Witte MA et al (2021) Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT. Bone Marrow Transplant 56:2651–2655. http://dx.doi.org/10.1038/s41409-021-01369-9
Hsu J, Chen Z, Shore T et al (2020) Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant 26:789–797. http://dx.doi.org/10.1016/j.bbmt.2019.12.766
Cho BS, Yahng SA, Min GJ et al (2021) Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients. Transpl Cell Ther 27. http://dx.doi.org/10.1016/j.jtct.2021.05.024. :774 e1- e12
Ruggeri A, Labopin M, Bacigalupo A et al (2018) Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. Cancer 124:1428–1437. http://dx.doi.org/10.1002/cncr.31228
Holtick U, Albrecht M, Chemnitz JM et al (2014) Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014:CD010189. http://dx.doi.org/10.1002/14651858.CD010189.pub2
Jain T, Tsai HL, Elmariah H et al (2023) Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration. Haematologica 108:3321–3332. http://dx.doi.org/10.3324/haematol.2023.283426
Raiola AM, Angelucci E, Sica S, Bacigalupo A (2023) Haploidentical bone marrow transplants with post transplant cyclophosphamide on day + 3 + 5: The Genova protocol. Blood Rev 62:101031. http://dx.doi.org/10.1016/j.blre.2022.101031
Imus PH, Tsai HL, Luznik L et al (2019) Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv 3:2608–2616. http://dx.doi.org/10.1182/bloodadvances.2019000155
Pasic I, Lipton JH, Kim DD et al (2020) Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. Ann Hematol 99:1377–1387. http://dx.doi.org/10.1007/s00277-020-04033-2
Ciurea SO, Shah MV, Saliba RM et al (2018) Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24:1232–1236. http://dx.doi.org/10.1016/j.bbmt.2017.09.005
Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919. http://dx.doi.org/10.1182/blood-2005-05-2004
Rambaldi A, Grassi A, Masciulli A et al (2015) Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 16:1525–1536. http://dx.doi.org/10.1016/S1470-2045(15)00200-4
Jain T, Tsai HL, Elmariah H et al (2023) Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration. http://dx.doi.org/10.21203/rs.3.rs-2691216/v1. Res Sq
Yu S, Fan Q, Sun J et al (2016) Haploidentical Transplantation Without In Vitro T-Cell Depletion Results in Outcomes Equivalent to Those of Contemporaneous Matched Sibling and Unrelated Donor Transplantation for Acute Leukemia. Med (Baltim) 95:e2973. http://dx.doi.org/10.1097/MD.0000000000002973
Luo Y, Xiao H, Lai X et al (2014) T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 124:2735–2743. http://dx.doi.org/10.1182/blood-2014-04-571570
Wang Y, Liu DH, Xu LP et al (2011) Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant 17:821–830. http://dx.doi.org/10.1016/j.bbmt.2010.08.023

Table 1 Patient charactbiaeristics.

Characteristics	Value
Age, median (range)	59(55-71)
Sex (male/female), N (%)	29(52.7%)/26(47.3%)
Diagnosis, N (%)
AML	34(61.8%)
ALL	6(10.9%)
MDS	10(18.2%)
CML	2(3.6%)
Lymphoma	2(3.6%)
MM	1(1.9%)
Disease status at SCT, N (%)
CR	38(69.1%)
PR	7(12.7%)
NR	10(18.2%)
Donor age, median (range)	33(19-45)
Donor/recipient relationship, N (%)
Child donor	54(98.2%)
Lateral relative donor	1(1.8%)
Donor/recipient gender, N (%)
Female to female	11(20.0%)
Female to male	11(20.0%)
Male to male	19(34.5%)
Male to female	14(25.5%)
Donor-recipient ABO blood type, N (%)
Match	20(36.4%)
Unmatch	35(63.6%)
HCT-CI,N (%)
HCT-CI 0	22(40.0%)
HCT-CI 1-2	25(45.5%)
HCT-CI ≥3	8(14.5%)
Stem cell source, N (%)
BM+PBSC	10(18.2%)
PBSC	45(81.8%)
MNC(*10^8/kg)	15.53(6.69-42.71)
CD34(*10^6/kg)	4.11(1.83-13.92)

AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia; MDS: Myelodysplastic syndromes; CML: Chronic myeloid leukemia; MM:Multiple myeloma; CR: Complete remission; PR: Partial response; NR: No remission; HCT-CI: Hematopoietic cell transplantation-specific comorbidity index; BM: Bone marrow; PBCS: Peripheral blood stem cells; MNC: Mononuclear cells

Table 2 Characteristics of infectious and noninfectious complications post-SCT

Variables	All patients n = 55, N (%)
CMV DNAemia	34 (61.8)
CMV disease	3 (5.5)
EBV DNAemia	23 (41.8)
Invasive fungal infection	6 (10.9)
Sepsis	5 (9.1)
COVID-19 infection	8 (14.5)

SCT：stem cell transplantation.

No competing interests reported.

Download PDF

Journal Publication

published 29 May, 2024

Read the published version in Annals of Hematology →

Editorial decision: Revision requested
04 Mar, 2024
Reviews received at journal
23 Feb, 2024
Reviewers agreed at journal
11 Feb, 2024
Reviewers invited by journal
11 Feb, 2024
Editor assigned by journal
28 Jan, 2024
Submission checks completed at journal
28 Jan, 2024
First submitted to journal
24 Jan, 2024

You are reading this latest preprint version

Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients

Status:

Journal Publication

Version 1

Abstract

Figures

INTRODUCTION

Methods

Statistical analysis

Results

Discussion

Declarations

Conflicts of interest

Funding

Author Contribution

References

Tables

Additional Declarations

Status:

Journal Publication

Version 1